Our new Marketplace Crash Course is here to help. Sign-up for free, learn at your own pace.
The pandemic led to an explosion of interest in and funding of biotech. That continues even as many sectors slow and recession fears grow.
The free market is pretty simple: There’s supply, there’s demand, they meet somewhere in the middle. If there’s a need, there’s a product. But sometimes, that system breaks down, as it has in the market for antibiotics.
In her new co-authored book, "The Genesis Machine," futurist Amy Webb walks readers through an imagined reproductive technology center.
It's become a cautionary tale for biotech investors. Are they heeding it?
Monsanto will report earnings today. One of the biggest factors for the agricultural giant’s business is how it responds to climate change. The company has invested in things like weather analysis and biotech to help farmers grow crops in the face of changing weather patterns. But climate change is an issue for Monsanto, too. Click […]
Researchers at the University of Texas are working on a way to produce mass quantities of nanocellulose -- a non-toxic construction and engineering material that's strong, saves trees, and could help reduce greenhouse gases.